The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer

Abstract

Our data suggest that metachronous bilateral breast cancer is associated with shorter disease-free survival than synchronous bilateral or unilateral breast cancer, although overall survival does not differ among the 3 groups. Patients with metachronous bilateral breast cancer should be followed particularly closely in order to detect recurrence early and maximize quality of life.

Clinicopathological Features in Bilateral Breast Cancer

“…As our study does not include unilateral patient data, the median age comparison cannot be made with the BBC, it is compatible with the literature data. In above studies where BBC and UBC case ages are compared, statistically significant difference in ages of both groups have not seen (Takahashi et al, 2005;Vuoto et al, 2010;Kheirelseid et al, 2011).…”

“…When compared with UBC historical data (70-80% IDC), the histopathology is similar in BBC patients (SC 81% and 76%; MC 70% and 76%; p=0.9) (Beckmann et al, 2001;Takahashi et al, 2005;Verkooijen et al, 2007;Vuoto et al, 2010 ). In a study comparing BBC and UBC the IDC ratio was reported as 66% (SC) and 63% (MC), respectively (Verkooijen et al, 2007).…”

“…In another study, age was stated as 58 years old in SC tumors, in MC tumors the first and second tumor ages were 51 and 58, respectively, UBC age was stated as 55 years old (Vuoto et al, 2010). Another study evaluated 46 Japanese BBC patients and mean SC age was reported as 50 years, mean MC age as 56 and for unilateral it was reported to be 51 years old (Takahashi et al, 2005). As our study does not include unilateral patient data, the median age comparison cannot be made with the BBC, it is compatible with the literature data.…”

Survival analysis of breast cancer patients with different chronic diseases through parametric and semi-parametric approaches

“…Surgery [14,15,25,29,36] and CA 15-3 marker [15] are the other factors that can be considered in the survival analysis. Furthermore, the combination of the following factors have been suggested across different studies: familial history [24], smoking [24], affected side [20,39], place of residence [29], number of involved lymph nodes [22,24,27,31,34,35,37], stage [5,6,8,17,25,26,42], stage of surgery [25], tumor size [16, 19, 20-24, 27, 28, 31, 34, 35, 37, 38, 41], complete clinical and pathological response [41], medicine [29], type of pathology [32], type of treatment [17,21], chemotherapy [25,33,36,37], neoadjuvant chemotherapy [18], radiotherapy [25,33,36], number of metastasis [30], bone pain [30], and time interval leading to bone metastasis [42]. No study has considered chronic diseases as an effective factor of survival analysis.…”

“…Metastasis [4,6,14,16,28,42], background of benign tumors [4], and age at diagnosis [4,5,16,INTRODUCTION 22,23,24,25,26,28,29,[32][33][34][35][36][37]39] were considered as the main factors in the survival analysis. Some studies emphasized on the factors such as hormone therapy (hormone receptor) [9,12,16,20,22,23,25,27,33,35,36,38], Her2 [9,11], grade [9,11,13,19,21,24,31,34,37,38], and lymph node involvement [11,19,…”